Article
We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.
All News
Article
The current NEJM reports that the use of the Pfizer mRNA vaccine (BNT162b2) demonstrated a very low risk for certain serious adverse events, including the risk of myocarditis (1 to 5 events per 100,000 persons).
Article
Can an antiinflammatory diet impact axial spondyloarthritis (axSpA)? A 6-month dietary intervention shows that adherence to a Mediterranean diet lowers disease activity in axSpA; but dietary adherence is often incomplete.
Article
The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an availabl
Article
A prospective study evaluated the value and associations with morning stiffness in patients with clinically suspect arthralgia, and found that the presence of morning stiffness increases the odds of inflammation (as detected by CRP and MRI synovitis).
Dr. John Cush
Tweet
Metanalysis of 36 studies, 608 RA-Bronchiectasis among 8569 RA pts; pooled bronchiectasis prevalence in RA was 18.7% (range 15.5% to 20.7%). Risk factors: older age, longer RA duration, genetics (CFTR & HLA), undetectable MBL biomarker https://t.co/SSRoTCYkHf
Dr. John Cush
Tweet
ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs
https://t.co/XO4DPXwGQi https://t.co/S9E3yENfDF
Dr. John Cush
Tweet
Brazilian national study of 319 SLE & 251,800 nonSLE pts hospitalized with COVID-19 showed that SLE increases risk of death (RR 1.74) & poor outcomeS (RR 1.39). Having lupus doubled (RR 2.2) the risk of risk of death. https://t.co/8VJjdOEuzS
Dr. John Cush
Tweet
A prospective study evaluated the value and associations with morning stiffness (MS) in patients with clinically suspect arthralgia (CSA), and found that the presence of MS increases the odds of inflammation (as detected by CRP and MRI synovitis).
https://t.co/4j5Zshn48a https://t.co/2UUguqpckF
Dr. John Cush
Tweet
2021–22 influenza season coincides with continued COVID infx & Sxs may be confused betw both. ACIP Influenza vaccination guidelines: 1. Annual flu vaccine rec to all >6mos; 2. COVID Vax can be given w/ Flu Vax; 3. give before Nov 2021 https://t.co/oIkl50GI0W
Dr. John Cush
Tweet
Comparing COVID vaccines in rheum dz pts - 45 took J&J vax compared to 994 on mRNA vaccines. Detectable Ab responses lower w/ J&J (80% vs 92%, p=0.03) than mRNA vax. RTX, MMF & steroids significantly depressed Ab responses https://t.co/6ZJU8EVF5n
Dr. John Cush
Tweet
Arthritis clinic referrals divided into 2 cohorts: (A) 163 w/ MSK US before visit; (B) 109 without initial MSK US. MSK-US at 1st visit reduced time to Dx from mean 31 to 12 days (p< 0.01), # of clinic visits, & increased odds of inflamm Dx (47% vs 27%) https://t.co/FaXLBlRlxy
Dr. John Cush
Tweet
MTX impairs COVID Vax responses in IMID pts from Ehrlangen & NYU. BNT162b2 mRNA COVID-19 vaccination in rheumatic pts (82) & 206 controls. Adequate immunogenicity seen in IMID & TNFi Rx >90%, but less (50-72%) w/ MTX (45) https://t.co/EvxZSAD6ve
Janet Pope
Tweet
#ClinicalPearl My pt’s rheumatoid nodules ⬇️ when she continued off her #methotrexate post #CovidVaccine. She restarted her JAKi + #plaquenil https://t.co/FqNX9k7FUN
Janet Pope
Tweet
Why do they always say larger RCTs are needed? RCT was >1000 and superiority of Bimekizumab to Secukinumab was shown. Maybe it is better to inhibit more than IL17A with added value of IL17F @RheumNow https://t.co/DAwZKxxinM
Eric Topol
Tweet
In the land of a surfeit of free vaccines, this is the dark day when we crossed the line of over 100,000 hospitalizations, more than 25,000 patients in the ICU (highest for the pandemic), over 1300 deaths, and over 186,000 new cases. https://t.co/A8KNIClCwX
Dr. John Cush
Tweet
Cognitive impairment (CI) is not a consequence of having rheumatoid arthritis (OR = 1.12, 0.80–1.58). Population survey study of 4262 adults >50 yrs. 63% of RA had normal cognition , 25% w/ CI, 12% dementia (similar to non-RA- 66%, 22%, 12%) https://t.co/7RFOk8Nrkm
Dr. John Cush
Tweet
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive RA.
https://t.co/szl5L7DGJG https://t.co/ScV51iJsA9
Dr. John Cush
Tweet
European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex
Dr. John Cush
Tweet
Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters
https://t.co/vT6185ycoG https://t.co/ImEejSrOPW
